^
Association details:
Biomarker:HER-2 L755S
Cancer:Breast Cancer
Drug:Herceptin (trastuzumab) (HER2 inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer

Excerpt:
Among the five cases with emerged HER2 mutations in metastatic lesions after one year of trastuzumab adjuvant treatment, two cases were identified with the K753E mutation, and the other three had the L755S mutation. K753E and L755S were confirmed to be drug-resistant mutations (resistant to trastuzumab and lapatinib). The mutation rate of HER2 was much higher than that in the primary tumor (2.24%, 28/1248).
DOI:
https://doi.org/10.1158/1078-0432.CCR-15-3036